Literature DB >> 22355010

Second-line therapies in hepatocellular carcinoma: emergence of resistance to sorafenib.

Augusto Villanueva1, Josep M Llovet.   

Abstract

Second-line therapies are needed for patients with advanced hepatocellular carcinoma who progress after sorafenib. Positive signals seen with brivanib in phase II studies, reported herein, have yet to be confirmed in phase III trials. Identification of the molecular mechanisms driving sorafenib resistance should guide drug development strategies in this setting. ©2012 AACR.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22355010      PMCID： PMC3336075          DOI： 10.1158/1078-0432.CCR-12-0151

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  13 in total

1.  Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

Authors:  Eunice L Kwak; Yung-Jue Bang; D Ross Camidge; Alice T Shaw; Benjamin Solomon; Robert G Maki; Sai-Hong I Ou; Bruce J Dezube; Pasi A Jänne; Daniel B Costa; Marileila Varella-Garcia; Woo-Ho Kim; Thomas J Lynch; Panos Fidias; Hannah Stubbs; Jeffrey A Engelman; Lecia V Sequist; WeiWei Tan; Leena Gandhi; Mari Mino-Kenudson; Greg C Wei; S Martin Shreeve; Mark J Ratain; Jeffrey Settleman; James G Christensen; Daniel A Haber; Keith Wilner; Ravi Salgia; Geoffrey I Shapiro; Jeffrey W Clark; A John Iafrate
Journal:  N Engl J Med       Date:  2010-10-28       Impact factor: 91.245

2.  Focal gains of VEGFA and molecular classification of hepatocellular carcinoma.

Authors:  Derek Y Chiang; Augusto Villanueva; Yujin Hoshida; Judit Peix; Philippa Newell; Beatriz Minguez; Amanda C LeBlanc; Diana J Donovan; Swan N Thung; Manel Solé; Victoria Tovar; Clara Alsinet; Alex H Ramos; Jordi Barretina; Sasan Roayaie; Myron Schwartz; Samuel Waxman; Jordi Bruix; Vincenzo Mazzaferro; Azra H Ligon; Vesna Najfeld; Scott L Friedman; William R Sellers; Matthew Meyerson; Josep M Llovet
Journal:  Cancer Res       Date:  2008-08-15       Impact factor: 12.701

3.  Shifting paradigms: the seeds of oncogene addiction.

Authors:  Charles L Sawyers
Journal:  Nat Med       Date:  2009-10       Impact factor: 53.440

4.  Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma.

Authors:  Joong-Won Park; Richard S Finn; Jun Suk Kim; Mark Karwal; Ruby K Li; Fuad Ismail; Melanie Thomas; Rosemarie Harris; Christine Baudelet; Ian Walters; Jean-Luc Raoul
Journal:  Clin Cancer Res       Date:  2011-02-24       Impact factor: 12.531

Review 5.  Modified RECIST (mRECIST) assessment for hepatocellular carcinoma.

Authors:  Riccardo Lencioni; Josep M Llovet
Journal:  Semin Liver Dis       Date:  2010-02-19       Impact factor: 6.115

Review 6.  Targeted therapies for hepatocellular carcinoma.

Authors:  Augusto Villanueva; Josep M Llovet
Journal:  Gastroenterology       Date:  2011-03-13       Impact factor: 22.682

7.  Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors.

Authors:  Oriol Casanovas; Daniel J Hicklin; Gabriele Bergers; Douglas Hanahan
Journal:  Cancer Cell       Date:  2005-10       Impact factor: 31.743

8.  Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening.

Authors:  Eric T Sawey; Maia Chanrion; Chunlin Cai; Guanming Wu; Jianping Zhang; Lars Zender; Alice Zhao; Ronald W Busuttil; Herman Yee; Lincoln Stein; Dorothy M French; Richard S Finn; Scott W Lowe; Scott Powers
Journal:  Cancer Cell       Date:  2011-03-08       Impact factor: 31.743

Review 9.  Design and endpoints of clinical trials in hepatocellular carcinoma.

Authors:  Josep M Llovet; Adrian M Di Bisceglie; Jordi Bruix; Barnett S Kramer; Riccardo Lencioni; Andrew X Zhu; Morris Sherman; Myron Schwartz; Michael Lotze; Jayant Talwalkar; Gregory J Gores
Journal:  J Natl Cancer Inst       Date:  2008-05-13       Impact factor: 13.506

10.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245
View more
  41 in total

Review 1.  Combination of local transcatheter arterial chemoembolization and systemic anti-angiogenic therapy for unresectable hepatocellular carcinoma.

Authors:  Eleni Liapi; Jean-Francois H Geschwind
Journal:  Liver Cancer       Date:  2012-11       Impact factor: 11.740

2.  Association of Notch1 with vasculogenic mimicry in human hepatocellular carcinoma cell lines.

Authors:  Man-Sheng Zhu; Lei-Bo Xu; Hong Zeng; Xiang-De Shi; Wen-Rui Wu; Chao Liu
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

Review 3.  Neddylation, a novel paradigm in liver cancer.

Authors:  Teresa Cardoso Delgado; Lúcia Barbier-Torres; Imanol Zubiete-Franco; Fernando Lopitz-Otsoa; Marta Varela-Rey; David Fernández-Ramos; María-Luz Martínez-Chantar
Journal:  Transl Gastroenterol Hepatol       Date:  2018-06-30

Review 4.  Advances in targeted therapies for hepatocellular carcinoma in the genomic era.

Authors:  Josep M Llovet; Augusto Villanueva; Anja Lachenmayer; Richard S Finn
Journal:  Nat Rev Clin Oncol       Date:  2015-06-09       Impact factor: 66.675

5.  Sorafenib and 2-Deoxyglucose Synergistically Inhibit Proliferation of Both Sorafenib-Sensitive and -Resistant HCC Cells by Inhibiting ATP Production.

Authors:  Ryan Reyes; Nissar A Wani; Kalpana Ghoshal; Samson T Jacob; Tasneem Motiwala
Journal:  Gene Expr       Date:  2016-11-16

6.  Natural history of untreatable hepatocellular carcinoma: A retrospective cohort study.

Authors:  Giuseppe Cabibbo; Marcello Maida; Chiara Genco; Pietro Parisi; Marco Peralta; Michela Antonucci; Giuseppe Brancatelli; Calogero Cammà; Antonio Craxì; Vito Di Marco
Journal:  World J Hepatol       Date:  2012-09-27

Review 7.  Targeting tumour-supportive cellular machineries in anticancer drug development.

Authors:  Matthias Dobbelstein; Ute Moll
Journal:  Nat Rev Drug Discov       Date:  2014-03       Impact factor: 84.694

Review 8.  Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma.

Authors:  Virginia Hernandez-Gea; Sara Toffanin; Scott L Friedman; Josep M Llovet
Journal:  Gastroenterology       Date:  2013-01-09       Impact factor: 22.682

9.  Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinoma.

Authors:  Bo Zhai; Xue-Ying Sun
Journal:  World J Hepatol       Date:  2013-07-27

10.  Acquisition of Cholangiocarcinoma Traits during Advanced Hepatocellular Carcinoma Development in Mice.

Authors:  Liyuan Li; Maoxiang Qian; I-Hsuan Chen; David Finkelstein; Arzu Onar-Thomas; Melissa Johnson; Christopher Calabrese; Armita Bahrami; Dolores H López-Terrada; Jun J Yang; W Andy Tao; Liqin Zhu
Journal:  Am J Pathol       Date:  2017-12-15       Impact factor: 4.307
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.